Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Abstract

Abstract The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.

Keywords

Affiliated Institutions

• Université Paris Cité FR
• Assistance Publique – Hôpitaux de Paris FR
• University Hospital Ulm DE
• The University of Melbourne AU
• Institute of Hematology & Blood Diseases Hospital CN
• Hôpital Saint-Louis FR
• Erasmus MC Cancer Institute NL
• The Royal Melbourne Hospital AU
• The University of Texas MD Anderson Cancer Center US
• Hospital de Sant Pau ES
• Technische Universität Dresden DE
• Leipzig University DE
• Erasmus MC NL
• Medical University of Lodz PL
• Peter MacCallum Cancer Centre AU
• Massachusetts General Hospital US
• University of Chicago US
• University Hospital Carl Gustav Carus DE
• Fred Hutch Cancer Center US
• Dana-Farber Cancer Institute US
• Amsterdam UMC Location Vrije Universiteit Amsterdam NL
• University of Washington US
• Nagasaki University JP
• Memorial Sloan Kettering Cancer Center US
• Queen Elizabeth Hospital Birmingham GB
• National Taiwan University Hospital TW
• Chinese Academy of Medical Sciences & Peking Union Medical College CN

Related Publications